MARKET

MTEM

MTEM

Molecular Templates Inc
NASDAQ
1.250
-0.070
-5.30%
After Hours: 1.225 -0.025 -2.00% 18:47 05/24 EDT
OPEN
1.340
PREV CLOSE
1.320
HIGH
1.340
LOW
1.160
VOLUME
53.52K
TURNOVER
0
52 WEEK HIGH
9.45
52 WEEK LOW
1.160
MARKET CAP
8.23M
P/E (TTM)
-0.2867
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MTEM last week (0513-0517)?
Weekly Report · 6d ago
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024
Molecular Templates reported earnings per share of 8 cents for the first quarter of 2024. The company reported revenue of $ million. This was better than the analyst estimate for revenue in the same period. The stock is up 2.7% in the last day.
Investorplace · 05/16 03:53
Molecular Templates, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/16 01:50
Molecular Templates GAAP EPS of $0.08, revenue of $11.09M beats by $5.19M
Molecular Templates, Inc. (MTEM) reports Q1 GAAP EPS of $.05. The company's revenue of $1.2 billion beats by $2 million. Molecular Templates is expected to report second quarter results on May 15. The stock is down 2.7% in the last week.
Seeking Alpha · 05/15 21:46
Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate
Benzinga · 05/15 21:13
*Molecular Templates 1Q EPS 8c >MTEM
Dow Jones · 05/15 21:12
MOLECULAR TEMPLATES Q1 NET INCOME USD 600 THOUSAND
Reuters · 05/15 21:11
MOLECULAR TEMPLATES, INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND CORPORATE UPDATE
Reuters · 05/15 21:11
More
About MTEM
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

Webull offers Molecular Templates Inc stock information, including NASDAQ: MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.